ILC Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- ILC Therapeutics's estimated annual revenue is currently $1.6M per year.
- ILC Therapeutics's estimated revenue per employee is $201,000
Employee Data
- ILC Therapeutics has 8 Employees.
- ILC Therapeutics grew their employee count by -20% last year.
ILC Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Operating Officer | Reveal Email/Phone |
4 | Senior Scientist | Reveal Email/Phone |
5 | Laboratory Technician | Reveal Email/Phone |
6 | Research associate | Reveal Email/Phone |
ILC Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $64.5M | 321 | 10% | N/A | N/A |
#2 | $25.5M | 127 | 5% | N/A | N/A |
#3 | $115.6M | 575 | 2% | N/A | N/A |
#4 | $21.7M | 108 | 4% | N/A | N/A |
#5 | $44.8M | 223 | 9% | N/A | N/A |
#6 | $15.1M | 75 | -67% | N/A | N/A |
#7 | $16.1M | N/A | N/A | N/A | |
#8 | $84.4M | 420 | 0% | N/A | N/A |
#9 | $8.8M | 44 | 10% | N/A | N/A |
#10 | $31M | 154 | 28% | N/A | N/A |
What Is ILC Therapeutics?
ILC Therapeutics is a specialist UK-based developer of hybrid interferons, a new engineered drug class with improved therapeutic profiles, enabling broad applications across multiple indications. Hybrid interferons combine favourable attributes of specific natural interferon sub-types to produce novel drug candidates designed to deliver reduced toxicity and improved efficacy.\n\nILC Therapeutic’s platform approach has produced two first-in-class lead candidates, Alfacyte™ and Dermacyte™ focused on antiviral and dermatological indications respectively, which are progressing towards the clinic.
keywords:N/AN/A
Total Funding
8
Number of Employees
$1.6M
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.3M | 8 | 14% | N/A |
#2 | $1.7M | 8 | 0% | N/A |
#3 | $0.7M | 8 | -11% | N/A |
#4 | $0.6M | 8 | -58% | N/A |
#5 | $1.3M | 8 | -11% | N/A |